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Abstract
Background: CDK5R1 plays a central role in neuronal migration and differentiation during central
nervous system development. CDK5R1 has been implicated in neurodegenerative disorders and
proposed as a candidate gene for mental retardation. The remarkable size of CDK5R1 3'-
untranslated region (3'-UTR) suggests a role in post-transcriptional regulation of CDK5R1
expression.
Results: The bioinformatic study shows a high conservation degree in mammals and predicts
several AU-Rich Elements (AREs). The insertion of CDK5R1 3'-UTR into luciferase 3'-UTR causes
a decreased luciferase activity in four transfected cell lines. We identified 3'-UTR subregions which
tend to reduce the reporter gene expression, sometimes in a cell line-dependent manner. In most
cases the quantitative analysis of luciferase mRNA suggests that CDK5R1 3'-UTR affects mRNA
stability. A region, leading to a very strong mRNA destabilization, showed a significantly low half-
life, indicating an accelerated mRNA degradation. The 3' end of the transcript, containing a class I
ARE, specifically displays a stabilizing effect in neuroblastoma cell lines. We also observed the
interaction of the stabilizing neuronal RNA-binding proteins ELAV with the CDK5R1 transcript in
SH-SY5Y cells and identified three 3'-UTR sub-regions showing affinity for ELAV proteins.
Conclusion: Our findings evince the presence of both destabilizing and stabilizing regulatory
elements in CDK5R1 3'-UTR and support the hypothesis that CDK5R1 gene expression is post-
transcriptionally controlled in neurons by ELAV-mediated mechanisms. This is the first evidence of
the involvement of 3'-UTR in the modulation of CDK5R1 expression. The fine tuning of CDK5R1
expression by 3'-UTR may have a role in central nervous system development and functioning, with
potential implications in neurodegenerative and cognitive disorders.
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CDK5R1 (Cyclin-dependent kinase 5 regulatory subunit 1)
encodes for p35, a protein required for the activation of
cyclin-dependent kinase 5 (CDK5), whose activity plays a
key role in central nervous system development [1]. Mon-
omeric CDK5 does not show any enzymatic activity,
requiring association with its regulatory partners p35 or
p39. During neuronal migration, p35-activated CDK5
phosphorylates NudEL, the homologous of an Aspergillus
nidulans gene involved in nuclear translocation and in
cytoskeletal organization of migrating neurons by dynein
regulation [2]. In mouse, Cdk5 modulates PAK kinases
and is implicated in actin reorganization, which may be
critical for neuron migration along radial glia [3]. In mice
lacking Cdk5 or p35, abnormal formation of cortical lay-
ers occurs: a loss of the Cdk5 pathway appears to affect
later migrating neurons as the cortical layers emerge from
the cortical plate [4,5], leading to severe cortical lamina-
tion defects, adult mortality and seizures [5,6]. The
absence of p39 did not produce aberrant phenotype, indi-
cating a predominant role of p35 in CDK5 activation [7].
It is also known that both Cdk5 and p35 concentrate at
the leading edges of axonal growth cones and have been
shown to regulate neuritis outgrowth in cortical neuron
culture [8]. The active CDK5/p35 complex is involved in
further processes required for central nervous system
development and function, such as axonal regeneration
[9], cellular differentiation, neuronal apoptosis [10],
learning and memory processes [11], synaptic transmis-
sion [12] and membrane trafficking during the outgrowth
of neuronal processes [13]. Hyperactivity of CDK5 medi-
ated by p25, a proteolytic fragment of p35, has been
implicated in the pathogenesis of several neurodegenera-
tive disorders, such as Alzheimer's disease [14], Parkin-
son's disease [15] and amyotrophic lateral sclerosis [16].
In fact, phosphorylated neurofilaments and their associ-
ated kinases, most of which are represented by CDK5,
were found in protein aggregates typical of neurodegener-
ative diseases. Findings on CDK5R1 deletion in patients
with NF1 microdeletion syndrome showing mental retar-
dation [17,18] and the recently reported CDK5R1 muta-
tions in non-syndromic mental retardation patients [19],
pinpoint the gene as a candidate for mental retardation
susceptibility in NF1 microdeletion syndrome and in a
subgroup of non-syndromic mental retarded patients.
More recently the CDK5/p35 complex has also been
reported to regulate several activities such as exocytosis,
gene transcription, tissue regeneration, senescence, apop-
tosis and hormone regulation also in extra-neuronal cells
[20].
Given the key role of CDK5R1 in the development, differ-
entiation and physiology of brain and its involvement in
extra-neuronal cell activities, it is conceivable that accu-
rate spatio-temporal regulation of its expression is
needed. CDK5R1 is characterized by an extended 3'-UTR
(2725 bp), which accounts for about 75% of the whole
transcript and is among the 5% longest annotated 3'-UTRs
[21]. We recently reported the presence of known regula-
tory elements in CDK5R1 3'-UTR such as a potential GY-
box motif (GUCUUCC, nt 1341–1347) and three puta-
tive AU-Rich Elements (AREs) at the 3' end of the tran-
script [19]; GY-box has been validated as microRNA target
in Drosophila [22,23]; AREs have a well known role in
post-transcriptional regulation of mRNA stability and
degradation through the binding of specific factors [24].
These features suggest a role for the 3'-UTR in the control
of CDK5R1 expression.
3'-UTRs have been shown to play crucial roles in a wide
variety of regulatory mechanisms [25], including modula-
tion of mRNA stability and degradation [24,26], transla-
tion efficiency [27], transport out of the nucleus and sub-
cellular localization of mRNA [28]. Expression of several
important nervous system genes, including genes encod-
ing neurotransmitter receptors, biosynthetic enzymes,
cytoskeletal proteins, growth factors and associated pro-
teins, are known to be regulated by functional elements in
their 3'-UTRs [29-33]. Indeed, post-transcriptional regula-
tion exerted by the 3'-UTR has been proposed as an effec-
tive counterpart to the mechanism of transcription in fine
modulation of gene expression, in particular during the
development of the central nervous system [34]. The
importance of 3'-UTRs in regulating gene expression is
also underlined by the finding that mutations affecting
the 3'-UTR can lead to serious pathologies [35,36]. The
role of the 3'-UTR for appropriated gene control has been
demonstrated [37] and it is possible that certain disorders
of neuronal plasticity and learning are due to perturba-
tions in 3'-UTR-mediated functions [35].
Thus, regulatory elements within the 3'-UTR of CDK5R1
are likely to be involved in the tuning of its expression
during central nervous system development and neuronal
migration, acting on mRNA stability, translation effi-
ciency and/or sub-cellular localization. Nevertheless, to
our knowledge, studies on CDK5R1 3'-UTR function have
not yet been reported.
In order to explore the role of CDK5R1 3'-UTR we have
predicted additional regulatory elements and performed
functional studies by means of dual luciferase assays and
mRNA quantification, observing that the 3'-UTR decreases
the reporter activity in different cell lines and that differ-
ent regulatory elements are present, some with stabilizing
and others with destabilizing function. We have identified
regulatory regions showing cell-line specificity, in particu-
lar we have identified a region showing a destabilizing
effect caused by increased mRNA degradation. We havePage 2 of 14
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taining a canonical ARE in two neuroblastoma cell lines
and have obtained evidence of binding of the neuronal-
specific ELAV (nELAV) proteins to CDK5R1 mRNA.
We report the first evidence on the involvement of
CDK5R1 3'-UTR in the modulation of gene expression.
These findings suggest that CDK5R1 3'-UTR may contrib-
ute to modulate its expression during central nervous sys-
tem development and functioning. The impairment of
this mechanism may be involved in the pathogenesis of
both neurodegenerative and cognitive disorders.
Results
CDK5R1 3'-UTR is highly conserved in mammals and 
contains several putative regulatory elements
We previously predicted a potential GY-box and three
putative AREs in CDK5R1 3'-UTR [19]. In order to refine
the search for potential Class I/II AREs we looked for the
AUUUA pentameric motif in the whole CDK5R1 3'-UTR
sequence: we found eight pentamers, among which two
are isolated and six are flanked at one or both sides by AU
stretches (Fig. 1A). None of these putative AREs show
AUUUA pentamers arranged in tandem, a feature of Class
II AREs, which indicates that these motifs might belong to
Class I. Nevertheless, only one of the eight potential AREs
(nt 2659–2671) corresponds perfectly to the consensus
sequence (WWWUAUUUAUUUW), according to the
ARED 3.0 database definition [38], while the other possi-
ble AREs show at least two mismatches.
Furthermore, we assessed the conservation between
human, mouse and rat CDK5R1 3'-UTRs, which have very
similar lengths (2725 bp, 2779 bp and 2683 bp, respec-
tively). The comparison, performed with the mVISTA tool
(Fig. 1A), indicates that the three sequences show several
regions of at least 100 bp with more than 70% identity,
notably in their proximal and terminal portions, with an
overall sequence identity of 76.8% and of 76.3% for the
human-mouse and the human-rat pair, respectively; the
most conserved portion of human CDK5R1 3'-UTR is the
3'-end, which has about 95% identity with both its mouse
and rat counterpart. Based on this analysis, the three most
terminal putative AREs (nt 2539–2551, nt 2636–2645
and nt 2659–2671) are completely conserved, while the
other five show one or more mismatches. It is worth not-
ing that, though the zebrafish Cdk5r1 3'-UTR, assembled
by EST analysis, shows a high level of divergence with the
sequences of mammals, the portion corresponding to the
CDK5R1 3'-UTR ARE that matches the ARED consensus is
nearly completely conserved, with the exception of only
one nucleotide (Fig. 1B). As far as the GY-box element is
concerned, there is only one mismatch between human,
mouse and rat, while this element seems to be absent in
zebrafish (data not shown).
As functional AREs are likely to be exposed in loops acces-
sible to AU-rich binding proteins, we predicted the
CDK5R1 3'-UTR secondary structure by using the Sfold
RNA-folding algorithm [39]: this analysis indicated that
in the most stable predicted structure only three possible
AREs are accessible in a single-stranded loop, in particular
the ARE that follows the ARED consensus criteria (nt
2659–2671) (Fig. 1C). In addition, this ARE is excluded
from RNA duplexes even in the other predicted secondary
structures, which show higher free energies (data not
shown). The secondary structure analysis of the region of
CDK5R1 3'-UTR surrounding the GY-box motif has previ-
ously been described [19].
Human CDK5R1 3'-UTR decreases reporter gene activity
The effect of the 3'-UTR on gene expression was studied
with the luciferase reporter assay. A construct was gener-
ated carrying the human CDK5R1 3'-UTR downstream of
the reporter gene (Fig. 2A).
The construct pGL4.71P-UTR was transiently transfected
in neuroblastoma cell lines SK-N-BE and SH-SY5Y, in
human embryonic kidney HEK-293 cells and breast
tumor MCF-7 cell lines. Luciferase activity was measured
24 hours after transfection.
The ARE region of Bcl2 gene from nt 942 to 1020 (Gen-
Bank M14745) has been used as a positive control (con-
struct pGL4.71P-b-ARE) as it was shown to have a
degradation activity on the mRNA [40]. pGL4.71P-b-ARE
leads to a decrease in luciferase activity in all four cell lines
(data not shown).
The luciferase activity of construct pGL4.71P-UTR was sig-
nificantly lower in the four transfected cell lines compared
to the insertion-less pGL4.71P vector (p < 0.01) (Fig. 2B).
The amount of reporter RNAs in the cell lines transfected
with the above luciferase constructs was quantified by
RealTime RT-PCR in order to identify whether the
decrease in luciferase activity was due to lower mRNA lev-
els. Data were normalized to Firefly to control for transfec-
tion efficiency and for the housekeeping gene GAPDH.
The levels of mRNA for each sample correlated with the
luciferase activity, with the exception of SH-SY5Y cells
where the transcript level is similar to the insertion-less
pGL4.71P vector (Fig. 2C).
CDK5R1 3'-UTR fragments differently affect reporter 
gene expression
In order to study whether the destabilizing effect on luci-
ferase activity can be assigned to specific regions, the 3'-
UTR was divided into six smaller fragments (C1-C6) each
containing at least one putative regulatory element
according to the in silico prediction described above, and
six luciferase reporter constructs were generated (Fig. 3A).Page 3 of 14
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Bioinformatic analysis of CDK5R1 3'-UTRF gure 1
Bioinformatic analysis of CDK5R1 3'-UTR. A) Human-mouse (above) and human-rat (below) conservation analysis of 
CDK5R1 3'-UTR using the mVISTA tool. Regions of at least 100 bp with identity greater than 70% are indicated in pink. The 
plots refer to the human CDK5R1 3'-UTR sequence (UTRdb ID: 3HSA086450). The position of the predicted regulatory ele-
ments is indicated. B) Multiple alignment of the last portion of human (Hs.), mouse (Mm.), rat (Rn.) and zebrafish (Dr.) CDK5R1 
3'-UTR. Stars represent fully conserved positions; the best ARE consensus is boxed in gray, the polyA sites are in bold. C) Rep-
resentation of the most stable secondary structure of the human CDK5R1 3'-UTR as predicted by the Sfold algorithm. The 
magnification shows the loop (arrow) corresponding to the ARE with the best consensus (nt 2659–2671).
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described above. Fragmentation of the 3'-UTR shows that
pGL4.71P-C2, pGL4.71P-C4 and pGL4.71P-C5 lead to a
considerable decrease in luciferase activity in all cell lines
(p < 0.01) indicating the presence of destabilizing regula-
tory elements (Fig. 3B). In particular, pGL4.71P-C2 has
the strongest decrease of luciferase activity observed, by
more than 80% compared to the control construct. The
other fragments decrease luciferase activity with signifi-
cant difference among cell lines, showing destabilization
in all lines with exception of HEK-293 for pGL4.71P-C1
and SK-N-BE and HEK-293 for pGL4.71P-C3. pGL4.71P-
C6 decreases luciferase activity only in HEK-293 and
MCF-7 cells (p < 0.01) and was not effective in neuroblas-
toma derived lines.
The quantitation of the above luciferase constructs
mRNAs in SK-N-BE, SH-SY5Y, HEK-293 and MCF-7 cell
lines by RealTime RT-PCR correlated in most cases with
the luciferase activity. Exceptions were the constructs
pGL4.71P-C2 in SH-SY5Y, pGL4.71P-C4 in SK-N-BE and
SH-SY5Y and pGL4.71P-C5 in MCF-7 in which the reduc-
tion of mRNA levels was not so marked as the correspond-
ent luciferase activity (Fig. 3C). These data were
normalized as previously described.
C2 fragment increases the rate of degradation of the 
reporter mRNA in an ARE independent way
As the pGL4.71P-C2 construct led to the strongest reduc-
tion of luciferase activity and mRNA level (Fig. 3) we per-
formed a degradation assay in order to determine whether
accelerated mRNA decay can contribute to the observed
reduction in luciferase activity and mRNA in SK-N-BE
cells.
We performed a real-time quantitative RT-PCR to com-
pare mRNA levels between the pGL4.71P-C2 and
pGL4.71P in SK-N-BE cells at various times after the addi-
tion of the transcriptional inhibitor DRB, which was ini-
tially added 24 hours following transfection. These data
were normalized on transfection efficiency by using Fire-
fly mRNA levels and GAPDH expression as housekeeping
gene. With respect to mRNA decay, the calculated half-life
of the pGL4.71P-C2 construct was 5,73 h, significantly
lower compared to the insertion-less construct pGL4.71P-
being > 8 h (Fig. 4A). These findings suggest that an accel-
erated degradation of mRNA has contributed to the
observed reduction in reporter gene expression and
mRNA associated with the C2 fragment.
In order to restrict the region causing the accelerate degra-
dation of C2 fragment and to determine the role of the
potential nt 992–1001 ARE motif, we divided the C2 frag-
ment, according to the presence of conserved stretches,
into 3 sub-fragments named C2.1 (138 bp), C2.2 (240
The 3'-UTR of CDK5R1 causes a decrease in luciferase activ-ityFigure 2
The 3'-UTR of CDK5R1 causes a decrease in luci-
ferase activity. A) Schematic representation of luciferase 
construct carrying the human 3'-UTR of CDK5R1. The 
pGL4.71P control construct does not contain CDK5R1 UTR 
sequences. The Renilla luciferase gene is indicated by the 
grey bars, and the region of the 3'-UTR is represented by the 
white bars. The numbers on the right indicate the 3'-UTR 
nucleotides included in the chimeric construct. Numbering 
starts from the first nucleotide beyond the stop codon for 
CDK5R1. Transcription was under the control of the SV40 
promoter (hatched bars) and the polyA site (black bars). B) 
Luciferase activity of pGL4.71P-UTR construct in SK-N-BE, 
SH-SY5Y, HEK-293 and MCF-7 cell lines assessed using the 
Dual-Glo Luciferase assay system. Cells were transiently co-
transfected with the pGL4.71P-UTR construct (Renilla luci-
ferase) and the pGL3 (Firefly luciferase) vector and were har-
vested 24 hours post-transfection (see Methods). Luciferase 
activity of the chimeric reporter gene, normalized for trans-
fection efficiency against the Firefly luciferase activity, is rep-
resented as a percentage of the activity observed in cells 
transfected with pGL4.71P (defined as 100%). Means ± s.d. 
luciferase values were obtained from at least four independ-
ent experiments (* p < 0.01 compared with the correspond-
ing pGL4.71P value). C) mRNA levels of the chimeric 
transcript. Total RNA was extracted from the cells harvested 
24 hours post-transfection, and the reporter gene mRNA 
levels were analyzed by RealTime PCR as described. mRNA 
levels of the chimeric reporter gene, normalized against the 
housekeeping gene GAPDH and for transfection efficiency 
against the Firefly luciferase mRNA levels, are represented as 
a percentage of the mRNA levels observed in cells trans-
fected with pGL4.71P (defined as 100%). Means ± s.d. luci-
ferase mRNA values were obtained from at least three 
independent experiments (* p < 0.01 compared with the cor-
responding pGL4.71P value).Page 5 of 14
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Decrease in steady state mRNA levels is due to altered rates of messenger degradation which is not ARE dependentFigure 4
Decrease in steady state mRNA levels is due to 
altered rates of messenger degradation which is not 
ARE dependent. A) Decay of pGL4.71P-C2 mRNA (black 
squares) compared with that of pGL4.71P control (black dia-
monds). SK-N-BE cells were transiently transfected with 
reporter gene constructs and the pGL3 (firefly luciferase) 
vector. 24 hours after transfection (time = 0 h), cells were 
treated with DRB. Total RNA was extracted after various 
time-points. RNA was reverse-transcribed and RealTime RT-
PCR was performed. Renilla luciferase transcript levels were 
normalized to GAPDH and firefly luciferase mRNAs. Data 
are expressed as percentage of RNA remaining after DRB 
addition and are representative of three independent experi-
ments. B) Schematic representation of luciferase constructs 
carrying C2 fragment and sub-fragments. C) Luciferase activ-
ity of the chimeric constructs in SK-N-BE, SH-SY5Y, HEK-
293 and MCF-7 cell lines. Cells, transiently co-transfected 
with the pGL4.71P- constructs (Renilla luciferase) and the 
pGL3 (Firefly luciferase) vector were harvested 24 hours 
post-transfection. Luciferase activity of the chimeric con-
structs normalized as described, is represented as a percent-
age of the activity observed in cells transfected with 
pGL4.71P (defined as 100%). Means ± s.d. luciferase values 
were obtained from at least four independent experiments (* 
p < 0.01 compared with the corresponding pGL4.71P value). 
D) mRNA levels of the chimeric transcripts. Total RNA was 
extracted from the cells harvested 24 hours post-transfec-
tion, and the reporter gene mRNA levels were analyzed by 
RealTime PCR. mRNA levels of the chimeric reporter gene 
normalized as described, are represented as a percentage of 
the mRNA levels observed in cells transfected with 
pGL4.71P (defined as 100%). Means ± s.d. luciferase mRNA 
values were obtained from at least three independent exper-
iments (* p < 0.01 compared with the corresponding 
pGL4.71P value).
CDK5R1 3'-UTR fragments differently affect reporter gene expressionFigure 3
CDK5R1 3'-UTR fragments differently affect reporter 
gene expression. A) Schematic representation of luciferase 
constructs carrying fragments of the 3'-UTR of CDK5R1. The 
pGL4.71P control construct contained no CDK5R1 UTR 
sequences. The chimeric constructs were created by cloning 
C1, C2, C3, C4, C5 and C6 3'-UTR fragments downstream 
of the Renilla luciferase gene. B) Luciferase activity of the six 
pGL4.71P- constructs in SK-N-BE, SH-SY5Y, HEK-293 and 
MCF-7 cell lines. Cells, transiently co-transfected with the 
pGL4.71P- constructs (Renilla luciferase) and the pGL3 (Fire-
fly luciferase) vector were harvested 24 hours post-transfec-
tion. Luciferase activity of the chimeric constructs 
normalized as described, is represented as a percentage of 
the activity observed in cells transfected with pGL4.71P 
(defined as 100%). Means ± s.d. luciferase values were 
obtained from at least four independent experiments (* p < 
0.01 compared with the corresponding pGL4.71P value). C) 
mRNA levels of the chimeric transcripts. Total RNA was 
extracted from the cells harvested 24 hours post-transfec-
tion, and the reporter gene mRNA levels were analyzed by 
RealTime PCR. mRNA levels of the chimeric reporter gene 
normalized as described, are represented as a percentage of 
the mRNA levels observed in cells transfected with 
pGL4.71P (defined as 100%). Means ± s.d. luciferase mRNA 
values were obtained from at least three independent exper-
iments (* p < 0.01 compared with the corresponding 
pGL4.71P value).
BMC Molecular Biology 2007, 8:111 http://www.biomedcentral.com/1471-2199/8/111bp) and C2.3 (365 bp) (Fig. 4B) the latter containing the
nt 992–1001 ARE. This fragments were cloned in the
above described reporter vector.
For each construct we performed a dual luciferase assay
and the quantization of the luciferase constructs mRNAs
as described above. Fragmentation of C2 shows that only
pGL4.71P-C2.1 leads to a considerable decrease in luci-
ferase activity and mRNA level in all cell lines (p < 0.01)
indicating the presence of unknown regulatory element/s
with a destabilizing effect (Fig. 4C and 4D). It is worth to
be noted that the C2.3 construct, containing the putative
ARE, does not reduce both luciferase and mRNA levels.
Class I ARE (nt 2659–2671) has a stabilizing effect in 
neuroblastoma cells while GY-box element does not affect 
reporter gene expression
We focused on the only canonical ARE (nt 2659–2671),
localized in the C6 fragment, which has the consensus
sequence for a class I ARE, and on the GY-box element,
localized in the C3 fragment.
To verify the actual function of the putative class I ARE,
the region from nt 2637 to 2687, encompassing the ARE
element, was deleted from C6 fragment (Fig. 5A). As
shown in Fig. 5B, pGL4.71P-C6del luciferase activity is
lower in comparison with that of the insertion-less plas-
mid (p < 0.01) in all four cell lines. It is worth noting that
in SK-N-BE and SH-SY5Y lines, the mRNA level of the
pGL4.71P-C6del construct decreases in sharp contrast
with the non-deleted construct (p < 0.01) indicating that
the class I ARE might act as a stabilizing element in these
cell lines (Fig. 5C).
Regarding the GY-box, the sequence GTCTTCC (nt 1341–
1347) was deleted from the C3 fragment. Normalized
luciferase activity was not affected by the constructs with
deleted GY-box in comparison with the corresponding
non deleted construct in all the tested cell lines (data not
shown), indicating the inactivity of this element in the cell
lines used.
CDK5R1 mRNA is a target of nELAV RNA-binding proteins
Since CDK5R1 3'UTR contains several putative ARE
sequences and the ARE-containing C6 fragment seems to
confer mRNA stability specifically in the neuronal SK-N-
BE and SH-SY5Y cell lines, we investigated whether neuro-
nal RNA-binding proteins (RBPs) are involved in the post-
transcriptional control of CDK5R1 mRNA. Among the
ARE-binding proteins the ELAV family is of interest since
three members (HuB, HuC, HuD) out of four are selec-
tively expressed in neurons and display a stabilizing effect
on target mRNAs. We tested the binding of the nELAV
RBPs to the CDK5R1 transcript by immunoprecipitating
endogenous mRNA-protein (mRNP) complexes from SH-
SY5Y cells with the pan-neuronal ELAV antibody. The
presence of CDK5R1 transcript together with GAP43,
which is a well-known target of nELAV proteins, was
detected by RT-PCR amplification of co-precipitated
Effect of deletion of the canonical Class I AREFigure 5
Effect of deletion of the canonical Class I ARE. A) 
Schematic representation of control and deleted constructs. 
The region containing Class I ARE element (nt 2637–2687) 
was deleted (hatched bar) from the pGL4.71P-C6 in con-
struct pGL4.71P-C6del by PCR. B) Luciferase activity of the 
two chimeric constructs in SK-N-BE, SH-SY5Y, HEK-293 and 
MCF-7 cell lines. Cells, transiently co-transfected with the 
pGL4.71P- constructs (Renilla luciferase) and the pGL3 (Fire-
fly luciferase) vector were harvested 24 hours post-transfec-
tion. Luciferase activity of the chimeric constructs 
normalized as described, is represented as a percentage of 
the activity observed in cells transfected with pGL4.71P 
(defined as 100%). Means ± s.d. luciferase values were 
obtained from at least four independent experiments (* p < 
0.01 compared with the corresponding pGL4.71P value). C) 
mRNA levels of the chimeric transcripts. Total RNA was 
extracted from the cells harvested 24 hours post-transfec-
tion, and the reporter gene mRNA levels were analyzed by 
RealTime PCR. mRNA levels of the chimeric reporter gene 
normalized as described, are represented as a percentage of 
the mRNA levels observed in cells transfected with 
pGL4.71P (defined as 100%). Means ± s.d. luciferase mRNA 
values were obtained from at least three independent exper-
iments (* p < 0.01 compared with the corresponding 
pGL4.71P value).Page 7 of 14
(page number not for citation purposes)
BMC Molecular Biology 2007, 8:111 http://www.biomedcentral.com/1471-2199/8/111mRNAs (Fig. 6A). We also used the irrelevant IgG anti-
body as a negative control in the assay to confirm that the
CDK5R1 mRNA was selectively isolated only from nELAV-
immunoprecipitated mRNP complexes
In order to map the binding of nELAV proteins along the
CDK5R1 transcript, we dissected the 3'UTR into four sub-
regions corresponding to the ARE containing fragments
C1, C2, C4-5 and C6, and used them in in vitro UV cross-
linking experiments. The radio-labelled C1, C2, C4-5 and
C6 riboprobes were incubated in the presence of brain
protein lysates and, after UV irradiation, the formed
mRNP complexes were immunoprecipitated by the
nELAV antibody and resolved on SDS-PAGE. We observed
that nELAV RBPs recognized and bound C1, C2 and C6
sub-regions, while the C4-5 fragment did not form mRNP
complexes with nELAV proteins (Fig. 6B).
Discussion
CDK5R1 is known to be a key regulator of central nervous
system development and functioning [1] and it has
recently been shown to have several extra-neuronal roles
[20]. CDK5R1 3'-UTR is longer than the eukaryotic 3'-UTR
average [24], belonging to the 5% longest annotated
3'UTRs [21] and was recently reported to contain poten-
tial post-transcriptional regulatory elements [19], suggest-
ing that it may be important for the control of CDK5R1
gene expression. The particular features of CDK5R1 3'-
UTR and the lack of functional data prompted us to study
its role in the control of gene expression by means of bio-
informatic analysis and dual luciferase and RealTime PCR
assays of chimeric constructs.
We have shown that the CDK5R1 3'-UTR can down-regu-
late luciferase expression and we assessed the presence of
different sub-regions that can independently affect tran-
script stability and, in a few cases, translational efficiency
in different cell lines.
The high degree of conservation showed by CDK5R1 3'-
UTR is strongly indicative of a functional role of this
region and suggests the presence of different post-tran-
scriptional regulatory elements [41]. In particular several
AREs were predicted, a feature typical of mRNAs with high
turnover rate [42], among which the nt 2659–2671 ARE
shows complete identity to the ARE consensus sequence,
according to the ARED 3.0 definition. Together with the
high phylogenetic conservation in mammals and
zebrafish and with the predicted accessibility to the bind-
ing of trans-acting factors, the functionality of this ele-
ment can be hypothesized. It is worth noting that
functional AREs are present in the 3'-UTR of many cyclin
mRNAs [43], raising the hypothesis that ARE-mediated
post-transcriptional regulation may be a common mecha-
nism for the control of expression in this class of genes, to
which CDK5R1 belongs.
The pGL4.71P-UTR construct shows a decreased luciferase
activity in all the cell lines according to mRNA level with
the exception of SH-SY5Y cells, showing an mRNA level
comparable to that of the control, which could be
explained by the action of mechanisms controlling the
translation. The overall effect of the large CDK5R1 3'-UTR
may be the result of a complex regulation mechanism
mediated by multiple 3'-UTR domains that act independ-
ently of each other, as has been already highlighted in
BCL2, Cox-2, VEGF and c-Fos mRNAs [40,44-48]. The dis-
section of 3'-UTR into 6 fragments, each containing at
least one predicted regulatory element, allowed us to
investigate the potential role of each region. All the chi-
meric constructs showed, in most of the studied cell lines,
a general decrease of luciferase activity. In most cases these
effects are likely to involve transcript stability rather than
CDK5R1 mRNA is bound by nELAV proteins in SH-SY5Y cellsFigure 6
CDK5R1 mRNA is bound by nELAV proteins in SH-
SY5Y cells. A) Endogenous mRNP complexes were selec-
tively immunoprecipitated from SH-SY5Y cells using the pan 
neuronal ELAV and the irrelevant IgG antibodies. The bound 
mRNAs were analyzed by RT-PCR with primer pairs specific 
for CDK5R1 (left panel) and GAP-43 (right panel). MW, 
Molecular weight marker; +, positive control (total SH-SY5Y 
cDNA); -, negative control (no sample). B) In vitro RNA-pro-
tein binding experiments were performed by UV cross-link-
ing of different P32-radiolabelled regions from CDK5R1 3'UTR 
and brain protein lysate. A selective immunoprecipitation of 
the formed mRNP complex was performed using the nELAV 
antibody (lanes 2–5). As a negative control a mix of all the 
different riboprobes was used and immunoprecipitated by 
the IgG antibody (-, lane 1), while GAP-43 3'UTR riboprobe 
was used as a positive control (+, lane 5).Page 8 of 14
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reporter activity levels corresponded, as determined by
RealTime RT-PCR experiments, to diminished mRNA lev-
els. In some instances the reduction of luciferase activity
may be the result of mechanisms affecting both mRNA
stability and translational efficiency. This effect is particu-
larly evident for C2 and 3'-UTR constructs in SH-SY5Y cell
line, suggesting that some elements influencing the
behavior of the entire CDK5R1 3'-UTR may be found in
the C2 region (Fig. 2 and 3).
The strong reduction of luciferase activity and RNA
induced by C2 fragment in all the transfected cell lines
suggests the presence of one or more regulatory elements
with a potent destabilizing function supported by the deg-
radation assay results. We found that the C2.3 fragment,
containing the only known putative element (nt 992–
1001 ARE), is not responsible for the low expression of
the C2 fragment and thus this ARE, which is not conserved
in rodents, is unlikely to be a destabilizing element. On
the other hand, the decreased expression of pGL4.71P-
C2.1 construct, in which none putative regulatory ele-
ments are predicted, prompts us to hypothesize the pres-
ence of novel regulatory elements in the C2.1 fragment.
Further studies will be necessary to identify the post-tran-
scriptional mechanisms leading to mRNA degradation of
the above construct.
The non-destabilizing effect detected in HEK-293 cells for
the C1 fragment and in SK-N-BE and SH-SY5Y for C6
allows us to hypothesize that these regions are bound by
cell-line specific stabilizing factors. The deletion in the C6
fragment of the canonical nt 2659–2671 ARE reduced
mRNA levels in all the analyzed cell lines, including SK-N-
BE and SH-SY5Y. This finding strongly suggests a stabiliz-
ing role of the canonical element in neuroblastoma-
derived cells through the binding of neuronal-specific sta-
bilizing factors expressed in SK-N-BE and SH-SY5Y cells
(Fig. 4). The prediction that this ARE is within a single-
stranded loop further supports this hypothesis. Several
ARE binding proteins are known, some of which promote
the stabilization of their target mRNAs, including cyclin
mRNAs [24,43]. Among these proteins, the neuronal spe-
cific nELAV RBPs, HuB, HuC and HuD, play a key role in
the induction of neuronal differentiation [49-51] and
have a stabilizing effect on several transcripts containing
AREs in their 3'-UTR [52,53]. The expression of HuB and
HuD has been demonstrated in several neuroblastoma
cell lines [54].
Our immunoprecipitation assays show that the neuronal-
specific nELAV RBPs bind to CDK5R1 transcript in SH-
SY5Y cells. The UV cross-linking experiments allowed us
to observe that C1, C2 and C6 sub-regions show affinity
for nELAV proteins in vitro while, although C4-5 contains
putative AREs, it does not bind to nELAV RBPs. The luci-
ferase activity together with the RealTime PCR results in
comparison to UV cross-linking data, suggest that the
binding shown by C1 and C2 regions for nELAV may be
not so effective in vivo as in the case of C6 region. This
finding might be explained by possible interactions of
these regions with further regulatory destabilizing factors
or to possible formation of unfavourable secondary
mRNA structures. According to the RNA-operon model,
trans-acting factors regulate mRNAs within a coordinated
pathway of RNA processing, providing cells of a fast and
dynamic tool to respond to environmental cues [55].
Our results on interaction of the nELAV factors with
CDK5R1 messenger in a neuronal cell line support the
hypothesis of a neuron-specific post-transcriptional regu-
lation of CDK5R1 expression. This mechanism may be
activated during central nervous system development to
rapidly increase dosage of a protein such as p35, charac-
terized by a rapid turnover through the ubiquitin-protea-
some pathway [56].
The generation of a construct with the canonical GY-box
motif deleted revealed the inactivity of this element in all
the cell lines used for the transfection experiments. These
data indicate that this motif does not seem to be involved
in the regulation of CDK5R1 expression.
Our findings have shown the presence of several regula-
tory elements in CDK5R1 3'-UTR, and for a few of them
we assessed a destabilizing or stabilizing function. The 3'-
UTR seems to contain some regulatory elements impli-
cated in rapid mRNA turnover which, as a consequence,
maintain the steady-state transcript at low levels, and oth-
ers which have a cell-specific stabilizing effect on the tran-
script that may contribute to rapidly increase the
expression of CDK5R1 during specific biological proc-
esses. Thus the 3'-UTR may exert a key role in fine tuning
of CDK5R1 expression that in turn might be crucial during
the complex processes underlying correct central nervous
system development and neuronal survival in which
CDK5R1 is involved [12,57]. The active CDK5-p35 com-
plex is strongly involved in neurofilament phosphoryla-
tion and its aberrant hyperactivity has been shown to be
implicated in neurodegenerative diseases [58]. It has
recently been demonstrated in mouse that p35 protein
level is a rate-limiting factor for the up-regulation of Cdk5
activity [59]. Thus an up-regulation of CDK5R1 expres-
sion in neurons may have pathological implications caus-
ing neurodegenerative diseases. On the other hand, the
absence of p35 leads to abnormalities in the laminar
structure of cerebral cortex, affecting actin-cyotskeletal
dynamics and microtubule regulation [60], and severe
mental retardation was shown by patients with NF1
microdeletion syndrome with the lack of one copy ofPage 9 of 14
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an up- or down-regulation of CDK5R1 expression, caused
by defective post-transcriptional mechanisms, may have
pathogenetic implications in neurodegenerative disorders
or cognitive impairment-based diseases, respectively.
Despite the fact that p35 activity has primarily been asso-
ciated with central nervous system, several extra-neuronal
roles of p35 have recently been shown, causing direct or
indirect effects on the organization of cytoskeletal struc-
tures [20]. The CDK5R1 expression is likely to be finely
controlled also in non-neuronal tissues. Our findings on
non-neuronal cell lines suggest that the 3'-UTR might be
involved in the post-transcriptional control of CDK5R1
expression in different tissues and that an alteration of
this mechanism may cause cellular dysfunction and dis-
ease. The large 3'-UTR of CDK5R1 is expected to contain
further regulatory elements, creating the possibility of
complex gene expression modulation [61].
Conclusion
Our study evidences for the first time the involvement of
3'-UTR in the modulation of CDK5R1 expression by the
presence of both destabilizing and stabilizing cis-regula-
tory elements in 3'-UTR, also supporting the hypothesis
that CDK5R1 gene expression is controlled in neurons by
nELAV-mediated mechanisms, with potential implica-
tions in neurodegenerative and cognitive disorders.
Additional studies are necessary to validate the biological
function of the predicted regulatory elements and to iden-
tify novel cis-acting regulatory motifs such as microRNA
target sites, in order to evince the role of 3'-UTR in the reg-
ulation of CDK5R1 expression. This search may eventu-
ally clarify the molecular basis of some neurological
diseases and in perspective the validated regulatory ele-
ments may represent new pharmacological targets for
treatment of neurodegenerative diseases.
Methods
Bioinformatic analysis
The human and mouse CDK5R1 3'-UTR sequences
(3HSA086450 and 3MMU05479) were obtained from the
UTRdb database [62] and correspond to the 3'-UTR of the
NCBI Reference Sequence cDNAs NM_003885 and
NM_009971, respectively [63]. The rat and zebrafish
Cdk5r1 3'-UTR sequences were assembled starting from
the ESTs annotated in the UCSC Genome Browser (rat
assembly version 3.4 (rn4) and zebrafish assembly ver-
sion 6 (Zv6)) using the CAP3 sequence assembly program
[64] with default parameter values. The AREs were
searched using the PatSearch program [65], looking for
the AUUUA pentamer; the results were compared with the
annotation proposed by the ARED 3.0 database [38].
Comparative analysis was carried out using the LAGAN
alignment program of mVISTA [66]. and the ClustalX pro-
gram [67]. The Sfold software was used for the prediction
of CDK5R1 3'-UTR secondary structure [39].
3'-UTR constructs
Segments of the human CDK5R1 3'-UTR were PCR-ampli-
fied using primers containing flanking XbaI recognition
sequence (Table 1). The segment in the 3'-UTR from
nucleotide 1167 to 1408 carrying the deletion of the GY-
box element, named C3del, was obtained by nested dele-
tion of the GY-box element (GCTCCTT) from nucleotide
1341 to 1347. Two partially overlapping PCR products
were synthesized for this purpose, as described by [68].
Briefly, the first PCR product was amplified with C3 FW
(see Table 1) and 5'-GGGCCTAGAATCCTCTGTAGT-
GTCTTCA-3' GYdel reverse primers. The second PCR
product was amplified with 5'-AGGCCCAGTCCACT-
GGGGA-3' (GYdel FW) and C3 REV primers. The 6 over-
lapping nucleotides are italicized in GYdel REV and GYdel
FW primers. The PCR products were ligated in the XbaI
restriction site downstream of the Renilla luciferase cod-
ing region of the pGL4.71 vector (Promega, Madison, WI)
in which the SV40 promoter region from the pGL3-Pro-
moter vector (Promega) was previously cloned to obtain
the pGL4.71P plasmid. Correct orientation of the insert
was verified by sequencing.
Cell Cultures
Human neuroblastoma SK-N-BE cells were cultured in
RPM-I medium with 10% fetal calf serum (FCS), 100 U/
ml penicillin-streptomycin, 0.01 mM L-glutamine,
sodium pyruvate 11 g/l and glucose 4.5 g/l. Human neu-
roblastoma SH-SY5Y cells and human embryonic kidney
HEK-293 cells were maintained in DMEM medium with
10% FCS, 100 U/ml penicillin-streptomycin and 0.01
mM L-glutamine. Human breast tumor MCF-7 cells were
cultured in RPM-I medium with 10% FCS, 100 U/ml pen-
icillin-streptomycin and 0.01 mM L-glutamine (all media
ingredients were obtained from Sigma-Aldrich, AS, Oslo,
Norway). Cultures were maintained at 37°C in a 5% CO2
incubator.
Cell transfection
For luciferase activity assays, 2.5–4.5 × 106 cells were
plated in 6-well dishes in 2 ml of medium 24 hours before
transfection. Cells were transfected at 60–70% confluence
with 300 ng of the pGL4.71P constructs containing differ-
ent CDK5R1 3'-UTR fragments. To normalize the value of
Renilla luciferase activity for transfection efficiency and
cell viability after transfection, the pGL3-Promoter Firefly
luciferase reporter gene was co-transfected (300 ng). For
transfection 2 µl of LIPOFECTAMINE 2000 (Invitrogen,
Burlington, ON) were used according to the manufac-
turer's instructions.Page 10 of 14
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Luciferase reporter assays were performed using the Dual-
Glo Luciferase Reporter Assay System (Promega). 24
hours after transfection, the culture medium was
removed, and cells were washed with phosphate-buffered
saline. Passive Lysis Buffer (350 µl of 1× buffer) was added
to each well, and plates were placed in a shaking incuba-
tor for 30 minutes at room temperature. For additional
lysis, two freeze-thaw cycles were performed in which the
cells were frozen to -80°C. 50 µl of Dual-Glo Luciferase
Reagent were added to 50–100 µl of lysate and incubated
for 30 minutes. Firefly luciferase luminescence (pGL3P
vector) was measured. Before measurement of Renilla
luciferase (pGL4.71P vector), 50 µl of the Stop & Glo rea-
gent were added to each well to quench the firefly luci-
ferase reaction. Renilla luciferase luminescence was
measured after an incubation of 30 minutes. Relative
Renilla luciferase light output was normalized to Firefly
luciferase output. Firefly-normalized luciferase activity for
the construct was compared with the insertion-less
pGL4.71P vector. The data were expressed as means ± s.d.
Statistical significance was calculated by using a Student's
t test. A difference between two means was considered sta-
tistically significant when p < 0.01.
Total RNA extraction, cDNA synthesis, and quantitative 
PCR
For total mRNA assays, 0.85–1.5 × 106 cells were plated in
a 25 cm2 flask in 4 ml of medium 24 hours before trans-
fection. Cells were co-transfected at 60–70% confluence
with 500 ng pGL3P and 500 ng of pGL4.71P construct
containing different CDK5R1 3'-UTR fragments, using 4 µl
of Lipofectamine 2000 (Invitrogen) according to the man-
ufacturer's instructions. Total RNA was extracted using
NucleoSpin RNA II Columns (Macherey-Nagel, Düren,
Germany) according to manufacturer's instructions. To
eliminate amplification of reporter plasmid DNA and
genomic DNA, total RNA was treated with Turbo DNA-
free (Ambion Inc., Austin, TX) at 37°C for 30 minutes.
RNA (4 µg) was reverse transcribed with High Capacity
cDNA Archive Kit (Applied Biosystems Inc., Foster City,
CA). The level of luciferase transcripts was determined
using RealTime quantitative reverse transcriptase PCR
using the TaqMan system (Applied Biosystems Inc.) using
specific primers and probes for Renilla luciferase, Firefly
luciferase and Glyseraldehyde-3-phosphate dehydroge-
nase (GAPDH). Renilla and Firefly luciferase quantifica-
tion data were normalized on expression of the
housekeeping gene GAPDH, and then the Renilla data
were normalized on transfection efficiency by using
Firelfy mRNA levels.
In mRNA decay assays SK-N-BE cells were treated with
5,6-dichloro-1-beta-D-ribobenzimidazole (DRB) (1 µg/
ml) 24 hours post-transfection to suppress the transcrip-
tion of the luciferase reporter gene. Cells were harvested at
0, 1.5, 3, 5 and 8 hours after treatment with DRB and RNA
isolated for real time RT-PCR analysis.
mRNP isolation and immunoprecipitation
Isolation of endogenous mRNPs was conducted with
minor modifications to [69] and as already described
Table 1: Oligonucleotides used to generate constructs of the 3'-UTR of the human CDK5R1 gene.
Fragment nt (bp) Sequence PCR annealing (°C)
UTR 1–2687 Fw: 5' GC TCTAGAATCGGTGAGCACTGTGCCTG 3'
Rev: 5' GCTCTAGAGAATCAGCACAGTACAAAAATAAAT 3'
62
C1 1–661 Fw: 5' GCTCTAGAATCGGTGAGCACTGTGCCTG 3'
Rev: 5' GCTCTAGAAGCAGCAGACAAGGGGGTAG 3'
62
C2 562–1226 Fw: 5' GCTCTAGATGAGCGGGTCTAGTGGAAAG 3'
Rev: 5' GCTCTAGAGAAAGAAAATCAATAAAGTACAC 3'
58
C2.1 562–661 Fw: 5' GCTCTAGATGAGCGGGTCTAGTGGAAAG 3'
Rev: 5' GCTCTAGAAGCAGCAGACAAGGGGGTAG 3'
58
C2.2 642–881 Fw: 5' GCTCTAGACTACCCCCTTGTCTGCTGCT 3'
Rev: 5' GCTCTAGAGTATGGCATCCCTCACCTTG 3'
58
C2.3 862–1226 Fw: 5' GCTCTAGACAAGGTGAGGGATGCCATAC 3'
Rev: 5' GCTCTAGAGAAAGAAAATCAATAAAGTACAC 3'
56
C3 1167–1408 Fw: 5' GCTCTAGAGTTTCCACCTTACCCTACTG 3'
Rev: 5' GCTCTAGAAGTGACCCTCTGCCTCCCC 3'
58
C4 1368–1688 Fw: 5' GCTCTAGATGCTGGAATAGGGACCTGG 3'
Rev: 5' GCTCTAGAGTGCTGTGTGAAGTCTGTG 3'
56
C5 1619–2326 Fw: 5' GCTCTAGAGGGACTGTCAGATAATCGGTG 3'
Rev: 5' GCTCTAGATCCAGGTTTACAAGAAAAAGAGAA 3'
62
C6 2273–2687 Fw: 5' GCTCTAGACCACAGGAATAATAGTTCAGG 3'
Rev: 5' GCTCTAGAGAATCAGCACAGTACAAAAATAAAT 3'
56
C6del 2273–2636 Fw: 5' GCTCTAGACCACAGGAATAATAGTTCAGG 3'
Rev: 5' GCTCTAGACAGCCAAACTGAGCTTCATG 3'
58
XbaI recognition site sequence is underlinedPage 11 of 14
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experiment and resuspended in RNP buffer (100 mM KCl,
5 mM MgCl2, 10 Mm HEPES pH 7.4, 0.5% NP-40).
Lysates were incubated in 1 ml NT2 buffer (50 mM Tris-
HCl pH 7.4, 150 mM NaCl, 1 mM MgCl2, 1 mM DTT, 20
mM EDTA, 0.05% NP-40) together with protein G Sepha-
rose-beads (GE Healthcare, Fairfield, CT) pre-coated with
4 µg of pan neuronal ELAV (16A11, Invitrogen) or Ig-G
(Santa Cruz Biotechnology, Santa Cruz, CA) antibodies.
RNA was phenol-cloroform extracted from immunopre-
cipitated mRNPs after treatment with proteinase K for 30
minutes. After DNaseI digestion, the isolated mRNAs were
retro-transcribed using SuperScriptII RT (Invitrogen) and
oligodT primers. RT-PCR was performed in two-rounds
amplifications (20 cycles for the first round and 20–25
cycles for the second one) with primers pairs for CDK5R1
(For CCACAGGAATAATAGTTCAGG; Rev GAATCAG-
CACAGTACAAAAATA) and GAP43 (For TGATGCT-
GCCACAGAGCAGG; Rev TGGGAAAGGACAGACTCACA
GACGTG). Amplifications products were run on 1% aga-
rose gel in TAE buffer.
In vitro transcription and UV cross-linking
Radio-labelled riboprobes were obtained by transcribing
0.5 µg restriction enzyme-linearized construct DNA with
20 U T7 RNA polymerase (Roche, Basel, Switzerland), 20
µCi α-[32P]UTP, 0.5 mM NTPs, and 20 U RNase inhibitor
(Promega). After template DNA removal by DNaseI diges-
tion, the resulting 32P-labelled riboprobes were purified
on ProbeQuant G-50 microcolumns (GE Healthcare). UV
cross-linking and immunoprecipitation experiments were
performed as previously described [53] using the pan neu-
ronal ELAV antibody (16A11, Invitrogen), which recog-
nizes the three neuronal ELAV proteins but not HuR.
300,000 cpm of riboprobes were incubated with 40 µg of
brain protein extract in 15 µl ligation buffer (1.3 mM
MgCl2, 19 mM HEPES-KOH pH 7.4, 1.5 mM ATP, 19 mM
Creatine phosphate) for 10 minutes at 30°C. After addi-
tion of 5 µg tRNA, samples were irradiated with UV light
(Stratalinker®, Stratagene) for 5 minutes and RNaseA-
treated (25 U) for 30 minutes. Immunoprecipitation was
conducted on UV cross-linked samples by the addition of
4 µg of the selected antibody pre-coated to protein G
Sepharose-beads. Immunocomplexes were then collected
by centrifugation at 14,000 × g for 30 seconds, washed
several times in NT2 buffer, run on a 10% SDS-PAGE and
analyzed by autoradiography.
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